Company Reports Q1 Revenue of $72.45M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $72.45M, consensus $92.07M. The company said, "The first quarter demonstrated important progress across the business while also reflecting revenue variability for RUCONEST. Joenja delivered strong revenue growth of 34% year over year, driven by robust patient uptake, reinforcing its role as an important growth driver still early in its lifecycle. We also made meaningful regulatory progress, including approval in Japan for APDS patients aged 4 and older and a positive CHMP opinion in Europe. In the U.S., constructive dialogue with the FDA following receipt of the CRL enabled us to already resubmit our pediatric sNDA for the two highest doses, which cover a meaningful proportion of children aged 4 to 11, and plan an additional sNDA submission for the lowest doses this summer."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHAR
Wall Street analysts forecast PHAR stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.340
Low
37.00
Averages
39.50
High
42.00
Current: 13.340
Low
37.00
Averages
39.50
High
42.00
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Accepts Joenja Resubmission for Pediatric APDS Treatment
- FDA Acceptance: Pharming Group announced that the FDA has accepted its supplemental New Drug Application for Joenja, aiming to provide treatment for children aged 4 to 11, marking the first approval in the U.S. and potentially improving the quality of life for APDS patients.
- Dosing Clarity: The application includes twice-daily dosing of 40 mg and 50 mg for pediatric patients weighing 27 kg or more, which is expected to cover a significant proportion of the target patient population, addressing the urgent market need for effective treatments.
- Clinical Trial Support: The resubmission is backed by Phase III clinical trial data showing significant improvements in two key clinical hallmarks of APDS over 12 weeks, indicating its potential in correcting immune deficiencies, which could open new market opportunities for the company.
- Future Plans: Pharming plans to submit a separate application for lower doses for patients weighing less than 27 kg in the second half of 2026, demonstrating the company's strategic commitment to meet the diverse needs of patients.
See More
Pharming to Participate in 2026 Jefferies Healthcare Conference
- Conference Participation: Pharming Group will participate in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, where CEO Fabrice Chouraqui will engage in a Fireside Chat Q&A session on June 4 at 11:05 AM EDT, highlighting the company's advancements in rare disease treatments.
- Live Webcast and Replay: The presentation will be available via live webcast and replay on Pharming's website under the 'Events and Presentations' and 'Our News' sections, ensuring that investors and the public can access real-time information and enhancing corporate transparency.
- Investor Relations: Pharming encourages interested investors to schedule one-on-one meetings with the management team by contacting investor@pharming.com or their Jefferies representative, demonstrating the company's commitment to investor engagement and relationship building.
- Company Background: Headquartered in Leiden, the Netherlands, Pharming Group N.V. focuses on developing and commercializing innovative medicines aimed at transforming the lives of patients with rare, life-threatening diseases, showcasing its strategic positioning and mission in the global healthcare landscape.
See More
Pharming Group Secures EU Approval for Joenja Treatment
- Drug Approval: Pharming Group's Joenja (leniolisib) has received marketing authorization from the European Commission, becoming the first and only approved treatment for activated PI3K delta syndrome (APDS) in patients aged 12 and older, marking a significant advancement in the rare immunodeficiency space.
- Market Launch Plans: Joenja is expected to launch in Germany in Q3 2026, with additional launches contingent on national reimbursement negotiations, laying the groundwork for the company's expansion in the European market.
- Regulatory Review Progress: Leniolisib is currently under regulatory review in Canada and several other countries, indicating its global market potential, while also being evaluated in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation, further broadening its indications.
- Stock Price Fluctuation: Pharming's stock closed at $12.60 on May 22, down 1.64%, but rebounded to $13.03 in after-hours trading, gaining 3.41%, reflecting positive market sentiment following the drug approval.
See More
Pharming Group Receives EU Marketing Authorization
- Marketing Authorization Granted: Pharming Group announced late Friday that the European Commission has granted marketing authorization for its product, marking a significant step in the company's expansion into the European market, which is expected to positively impact sales growth.
- Product Potential Unleashed: With the marketing authorization, Pharming's product will be able to be sold across the EU, enhancing the company's competitive position and potentially attracting more investor interest in its future developments.
- Strategic Positioning Enhanced: The authorization allows Pharming to more effectively penetrate the European market, leveraging local sales networks and resources to strengthen its market position in the biopharmaceutical industry.
- Future Growth Expectations: With the implementation of the marketing authorization, Pharming anticipates revenue growth, further advancing its strategic goals in the global biopharmaceutical sector, particularly in meeting patient needs.
See More
Joenja® Approved in EU for APDS Treatment
- First Approved Treatment: Joenja® (leniolisib) is the first approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the European Union, applicable to adults and pediatric patients aged 12 and older, marking a significant advancement in the rare immunodeficiency field.
- Launch in Germany: The first European launch of Joenja® is expected in Germany in Q3 2026, with additional launches anticipated based on the completion of national reimbursement negotiations, demonstrating the company's strategic commitment to global market expansion.
- Clinical Trial Support: The approval is based on a multinational, triple-blind, placebo-controlled Phase II/III clinical trial that showed statistically significant improvements in immune dysregulation and immunodeficiency markers in 31 patients, indicating its efficacy in treating APDS.
- Long-term Safety Data: The application included long-term open-label extension data from 37 patients, demonstrating good safety and tolerability over a median of three years of use, further enhancing its prospects in rare disease treatment.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
FDA Accepts Joenja Resubmission for Pediatric APDS Treatment
- FDA Acceptance: Pharming Group announced that the FDA has accepted its supplemental New Drug Application for Joenja, aiming to provide treatment for children aged 4 to 11, marking the first approval in the U.S. and potentially improving the quality of life for APDS patients.
- Dosing Clarity: The application includes twice-daily dosing of 40 mg and 50 mg for pediatric patients weighing 27 kg or more, which is expected to cover a significant proportion of the target patient population, addressing the urgent market need for effective treatments.
- Clinical Trial Support: The resubmission is backed by Phase III clinical trial data showing significant improvements in two key clinical hallmarks of APDS over 12 weeks, indicating its potential in correcting immune deficiencies, which could open new market opportunities for the company.
- Future Plans: Pharming plans to submit a separate application for lower doses for patients weighing less than 27 kg in the second half of 2026, demonstrating the company's strategic commitment to meet the diverse needs of patients.
See More
Pharming to Participate in 2026 Jefferies Healthcare Conference
- Conference Participation: Pharming Group will participate in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, where CEO Fabrice Chouraqui will engage in a Fireside Chat Q&A session on June 4 at 11:05 AM EDT, highlighting the company's advancements in rare disease treatments.
- Live Webcast and Replay: The presentation will be available via live webcast and replay on Pharming's website under the 'Events and Presentations' and 'Our News' sections, ensuring that investors and the public can access real-time information and enhancing corporate transparency.
- Investor Relations: Pharming encourages interested investors to schedule one-on-one meetings with the management team by contacting investor@pharming.com or their Jefferies representative, demonstrating the company's commitment to investor engagement and relationship building.
- Company Background: Headquartered in Leiden, the Netherlands, Pharming Group N.V. focuses on developing and commercializing innovative medicines aimed at transforming the lives of patients with rare, life-threatening diseases, showcasing its strategic positioning and mission in the global healthcare landscape.
See More
Pharming Group Secures EU Approval for Joenja Treatment
- Drug Approval: Pharming Group's Joenja (leniolisib) has received marketing authorization from the European Commission, becoming the first and only approved treatment for activated PI3K delta syndrome (APDS) in patients aged 12 and older, marking a significant advancement in the rare immunodeficiency space.
- Market Launch Plans: Joenja is expected to launch in Germany in Q3 2026, with additional launches contingent on national reimbursement negotiations, laying the groundwork for the company's expansion in the European market.
- Regulatory Review Progress: Leniolisib is currently under regulatory review in Canada and several other countries, indicating its global market potential, while also being evaluated in two Phase II clinical trials for primary immunodeficiencies with immune dysregulation, further broadening its indications.
- Stock Price Fluctuation: Pharming's stock closed at $12.60 on May 22, down 1.64%, but rebounded to $13.03 in after-hours trading, gaining 3.41%, reflecting positive market sentiment following the drug approval.
See More
Pharming Group Receives EU Marketing Authorization
- Marketing Authorization Granted: Pharming Group announced late Friday that the European Commission has granted marketing authorization for its product, marking a significant step in the company's expansion into the European market, which is expected to positively impact sales growth.
- Product Potential Unleashed: With the marketing authorization, Pharming's product will be able to be sold across the EU, enhancing the company's competitive position and potentially attracting more investor interest in its future developments.
- Strategic Positioning Enhanced: The authorization allows Pharming to more effectively penetrate the European market, leveraging local sales networks and resources to strengthen its market position in the biopharmaceutical industry.
- Future Growth Expectations: With the implementation of the marketing authorization, Pharming anticipates revenue growth, further advancing its strategic goals in the global biopharmaceutical sector, particularly in meeting patient needs.
See More
Joenja® Approved in EU for APDS Treatment
- First Approved Treatment: Joenja® (leniolisib) is the first approved treatment for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the European Union, applicable to adults and pediatric patients aged 12 and older, marking a significant advancement in the rare immunodeficiency field.
- Launch in Germany: The first European launch of Joenja® is expected in Germany in Q3 2026, with additional launches anticipated based on the completion of national reimbursement negotiations, demonstrating the company's strategic commitment to global market expansion.
- Clinical Trial Support: The approval is based on a multinational, triple-blind, placebo-controlled Phase II/III clinical trial that showed statistically significant improvements in immune dysregulation and immunodeficiency markers in 31 patients, indicating its efficacy in treating APDS.
- Long-term Safety Data: The application included long-term open-label extension data from 37 patients, demonstrating good safety and tolerability over a median of three years of use, further enhancing its prospects in rare disease treatment.
See More
Pharming Releases 2026 Financial Guidance Amid Revenue Decline
- Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
- Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
- Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
- 2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.
See More
